全球細胞生物學研究市場（2024-2030）

單細胞技術和基因組學工具的進步推動了細胞生物學研究的變革性成長

本報告研究了全球細胞生物學研究市場，預計該市場將在2024年至2030年間實現高速成長，並取得顯著的收益里程碑。該成長反映了儀器、耗材和軟體平台技術創新的加速，並受到資料驅動的研究模式、日益增多的學術界與生物製藥公司的合作以及數位化實驗室工作流程的推動。此外，新型細胞治療方法的出現以及生物學研究日益複雜的發展，對更先進的工具和工作流程提出了更高的要求。

該分析包括：

• 推動和限制細胞生物學研究解決方案採用的因素
• 依產品類型（儀器、消耗品和試劑、軟體）、最終用途（製藥、學術和研究、臨床實驗室）、技術（單細胞分析、活細胞成像、高通量篩檢、流式細胞技術、細胞培養、CRISPR 和基因編輯、其他）和地區（北美、歐洲、亞太、拉丁美洲、中東和非洲）細分
• 各產品領域和技術領域的知名公司

透過評估行業細分、新興經營模式、收益和預測來確定細胞生物學研究領域的關鍵成長機會。

研究期間為2024年至2030年，以2024年為基準年，2025年至2030年為預測期間。

收益及預測

2024年營收將達到 199.4億美元，2024-2030年期間的年複合成長率為 7.5%。

分析範圍

• 該分析考察了全球細胞生物學研究市場，其中包括分析樣本中的細胞以研究其結構、功能和行為。
• 對細胞生物學研究市場的關注是由快速的技術進步和對提高研究效率和可重複性的創新解決方案日益成長的需求所驅動的。
• 細胞生物學研究涵蓋廣泛的技術和方法，包括細胞培養、成像、單細胞分析和多組體學方法。這些領域的發展推動疾病機制、再生醫學和生物製藥領域的探索。
• 細胞生物學領域的關鍵創新包括高通量篩檢（HTS）、先進成像技術和人工智慧驅動的資料分析的整合。這些發展使研究人員能夠更深入地了解細胞過程，改善藥物發現和治療策略。
• 市場可細分為解決方案、應用和產品/服務。本研究重點關注細胞生物學領域的新興技術和研究工具，以進行收益估算和預測分析。
• 區域細分僅依產品類型進行。

三大戰略要務對細胞生物學研究產業的影響

顛覆性技術

• 單細胞RNA測序、CRISPR基因編輯、空間轉錄組學和AI驅動的圖像分析等新興技術重塑細胞生物學研究。這些創新使能夠更詳細、即時地了解細胞功能，為疾病建模、再生醫學和藥物研發領域的突破奠定基礎。
• 製造商和研究供應商投資可擴展且易於使用的工具，這些工具集自動化、多組體學功能和即時分析於一體。人們越來越重視整合儀器、軟體和人工智慧演算法的系統，以簡化細胞工作流程並提供可操作的洞察。新興企業和成熟的供應商都越來越注重靈活性、模組化和可自訂性，以滿足不斷變化的研究需求。

變革大趨勢

• 人口老化、慢性疾病、新興流行病以及個人化醫療的轉變等全球性挑戰，推動對更深入的細胞洞察的需求。隨著研究人員試圖理解更複雜生理環境下的細胞行為，人們對類器官、3D細胞培養物和原代細胞的興趣日益濃厚。
• 市場相關人員調整其研發策略，以應對公共衛生優先事項和全球研究挑戰。對彌合基礎科學與臨床應用之間差距的轉化研究工具的需求快速成長。這些大趨勢推動對細胞化驗分析和高內涵篩檢（HCS）平台的長期投資。

產業融合

• 細胞生物學與資料科學、微流體、材料科學和機器人技術的交叉日益緊密。這種跨學科合作推動結合自動化細胞處理、高通量篩選和高級分析技術的下一代平台的開發。這種融合加快發現的步伐，同時減少差異性和人為錯誤。
• 主要企業與高科技公司和學術機構合作，開發可互通的智慧實驗室解決方案。整合雲端運算、機器學習和實驗室自動化的平台正成為現代細胞生物學實驗室不可或缺的一部分，催生新的市場和使用案例，尤其是在藥物研發、合成生物學和精準醫療領域。

主要競爭對手

影像技術

• Revvity
• Zeiss Microscopy
• Nikon Instruments Inc.
• Leica Microsystems
• Evident Scientific
• Bruker Corporation
• JEOL Ltd.
• Hitachi High-Tech Corporation
• PerkinElmer Inc.
• Molecular Devices LLC
• GE Healthcare Life Sciences
• Yokogawa Electric Corporation
• Amnis Corporation（part of Luminex Corporation）
• Cytek（R）
• Chemometec A/S

流式細胞儀技術

• BD Biosciences
• Beckman Coulter（Danaher Corporation）
• Miltenyi Biotec
• Sony Biotechnology Inc.
• Fluidigm Corporation
• Amnis 公司（Luminex 公司的一部分）
• Nexcleom Bioscience LLC
• Chemometec A/S

細胞培養技術

• Corning Incorporated
• Greiner Bio-One International GmbH
• Thermo Fisher Scientific
• Lonza Group
• InSphero AG
• Kuraray Co., Ltd.
• Sartorius AG
• Eppendorf AG
• Appilkon Biotechnology（part of Getinge）
• Merck KGaA
• GE Healthcare Life Sciences
• Cellares
• CellulaRevolution
• TissenBioFarm
• Scinobuh Biotech

細胞分離技術

• Miltenyi Biotec
• BD Biosciences
• Beckman Coulter（Danaher Corporation）
• Fluidigm Corporation
• Dolomite Microfluidics

促進因素

• 研究技術的進步，尤其是 CRISPR/Cas9、基因編輯和新一代定序（NGS），徹底改變研究能力，實現精準基因編輯和快速基因序列測定，並推動基因治療和腫瘤學領域的創新。這些技術使研究人員能夠精準編輯基因，拓展研究機會，加速腫瘤學、遺傳學和個人化醫療領域的發現。人工智慧和自動化技術的不斷發展與整合，也提高實驗室流程的效率和可重複性。
• 個人化醫療和再生醫學的需求正促使人們更加重視細胞療法，包括幹細胞療法和基因改造免疫細胞。各大公司正致力於開發幹細胞等細胞療法解決方案，幹細胞在再生醫學中正變得非常重要，可用於治療阿茲海默症、糖尿病和心臟病等疾病。
• 全球癌症、糖尿病和心血管疾病等慢性疾病的增多，推動了對更先進研究工具和解決方案的需求，增加了再生醫學和基因治療等領域的資金投入和創新，重點關注個性化治療方案，以更有效地管理這些疾病。
• 學術機構、生物技術公司和製藥公司之間的策略夥伴關係推動細胞生物學研究市場的成長。這些合作共用專業知識、資源和資金，加快了創新步伐，並促進了新治療方法和研究工具的開發。
• 市場成長受到監管環境變化的推動，尤其是在基因編輯和幹細胞治療領域。政府和監管機構對生物技術、臨床試驗和產品核可的支持增加，這表明研究和商業化的法規環境更加有利，刺激了細胞生物學研究的創新。

成長限制因素

• 基因編輯平台和高通量定序系統等先進細胞生物學研究工具和技術的高昂研發成本仍是一大障礙。研究機構和生技公司面臨高昂的初始投資，這阻礙了創新，也使得預算有限的小型機構和實驗室難以負擔這些技術。
• 在全球範圍內，CRISPR/Cas9、NGS 和 PCR 等先進細胞生物學研究技術的專業人才短缺。專業的培訓和教育課程對於滿足日益成長的人才需求非常重要。缺乏經過充分培訓的人才可能會阻礙這些技術的普及和有效使用。
• 儘管技術進步日新月異，但工具的複雜性以及在準確性、可重複性和可擴展性方面的技術限制仍然存在。 NGS 資料的解讀和基因編輯效率的挑戰仍有待解決。
• 隨著越來越多的細胞生物學研究使用患者基因資料和敏感的生物資訊，資料隱私和安全審查方面的擔憂日益凸顯。 《一般資料保護規範》（GDPR）等日益嚴格的資料保護條例，為管理大型資料集的公司和研究機構帶來了挑戰。安全漏洞可能會削弱人們對該技術的信任，並減緩市場成長。

目錄

調查範圍

成長環境：細胞生物學研究市場的轉型

• 為什麼成長變得越來越困難
• 策略要務
• 三大策略要務對細胞生物學研究產業的影響

細胞生物學研究市場生態系統

• 競爭環境
• 主要競爭對手

細胞生物學研究市場的成長動力

• 成長指標
• 成長動力
• 成長限制因素
• 預測考慮因素
• 收益預測
• 依產品分類的收益預測
• 依最終用戶的收益預測
• 依技術分類的收益預測
• 各地區收益預測
• 收益預測分析
• 依產品分類的收益預測分析
• 依最終用戶的收益預測分析
• 依技術分類的收益預測分析
• 各地區收益預測分析
• 價格趨勢及預測分析
• 收益分配
• 公司矩陣
• 企業投資組合
• 收益佔有率分析

值得關注的公司：單細胞分析

• 值得關注的公司：活細胞成像
• 值得關注的公司：高通量篩檢
• 值得關注的公司：流式細胞技術
• 值得關注的公司：細胞培養
• 值得關注的公司：CRISPR 與基因編輯
• 值得關注的公司：其他

成長動力：設備

• 成長指標
• 收益預測
• 各地區收益預測
• 預測分析

成長動力：消耗品和試劑

• 成長指標
• 收益預測
• 各地區收益預測
• 預測分析

成長動力：軟體

• 成長指標
• 收益預測
• 各地區收益預測
• 預測分析

細胞生物學研究市場的成長機會

• 成長機會 1：創建用於工作流程整合的軟體解決方案
• 成長機會2：將單細胞分析與基因體學及基因編輯工具結合
• 成長機會3：為生物製藥和轉化研究開發客製化解決方案

附錄與後續步驟

Cell Biology Research is Experiencing Transformational Growth due to Advances in Single-Cell Technologies and Genomics Tools

In the study, Frost & Sullivan examines the global cell biology research market. The market is projected to register high growth between 2024 and 2030, reaching significant revenue milestones. This growth reflects accelerating innovation across instrumentation, consumables, and software platforms, with a firm push from data-driven research models, increased academic and biopharma collaboration, and the digitalization of lab workflows. In addition, the emergence of new cell-based therapies and the increasing complexity of biological research call for more sophisticated tools and workflows.

This analysis includes:

• Factors driving and restraining the adoption of cell biology research solutions
• Segmentation by product type (instruments, consumables and reagents, software), end use (pharma, academia and research, clinical labs), technology (single-cell analysis, live-cell imaging, high-throughput screening, flow cytometry, cell culture, CRISPR and gene editing, others), and region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa)
• Notable companies in each product segment and technology

Frost & Sullivan also identifies the major growth opportunities in the cell biology research space by evaluating the industry segments, emerging business models, and revenues and forecasts.

The study period is 2024-2030, with 2024 as the base year and 2025-2030 as the forecast period.

Revenue Forecast

The revenue estimate for the base year 2024 is $19.94 billion, with a CAGR of 7.5% for the study period 2024-2030.

Scope of Analysis

• This analysis examines the global cell biology research market, which involves analyzing cells from a sample to study their structure, function, and behavior.
• Frost & Sullivan has focused on the cell biology research market due to its rapid advancements in technology and increasing demand for innovative solutions that enhance research efficiency and reproducibility.
• Cell biology research encompasses a wide range of techniques and technologies, including cell culture, imaging, single-cell analysis, and multomics approaches. Advances in these areas are driving discoveries in disease mechanisms, regenerative medicine, and biopharmaceutical development.
• Key innovations in cell biology include the integration of high-throughput screening (HTS), advanced imaging techniques, and AI-driven data analysis. These developments enable researchers to gain deeper insights into cellular processes, improving drug discovery and therapeutic strategies.
• The market can be categorized into solutions, applications, and product and service offerings. This study focuses on emerging technologies and research tools within cell biology for revenue estimation and forecast analysis.
• The regional breakdown is only provided for the product type segment.

The Impact of the Top 3 Strategic Imperatives on the Cell Biology Research Industry

Disruptive Technologies

• Why: Emerging technologies such as single-cell RNA sequencing, CRISPR gene editing, spatial transcriptomics, and AI-powered image analysis are reshaping cell biology research. These innovations enable a more detailed, real-time, and functional understanding of cells, supporting breakthroughs in disease modeling, regenerative medicine, and drug discovery.
• Frost Perspective: Manufacturers and research suppliers are investing in scalable, user-friendly tools that combine automation, multiomics capabilities, and real-time analytics. There is growing emphasis on systems that integrate instruments, software, and AI algorithms to streamline cellular workflows and deliver actionable insights. Start-ups and larger vendors alike increasingly focus on flexibility, modularity, and customization to meet evolving research needs.

Transformative Megatrends

• Why: Global challenges, including an aging population, chronic disease burden, emerging pandemics, and the shift toward personalized medicine, are driving demand for deeper cellular insights. As researchers seek to understand cell behavior in more complex physiological contexts, interest in organoids, 3D cell cultures, and primary cells has surged.
• Frost Perspective: Market players are aligning their R&D strategies with public health priorities and global research agendas. The demand for translational research tools that bridge basic science and clinical application is growing fast. These megatrends are fueling long-term investment in cell-based assays and high-content screening (HCS) platforms.

Industry Convergence

• Why: Cell biology increasingly intersects with data science, microfluidics, materials science, and robotics. These cross-industry collaborations are driving the development of next-gen platforms that combine automated cell handling, HTS, and advanced analytics. This convergence is accelerating the pace of discovery while reducing variability and manual errors.
• Frost Perspective: Leading vendors are partnering with tech companies and academic institutions to develop interoperable, smart lab solutions. Platforms that integrate cloud computing, machine learning, and lab automation are becoming essential for modern cell biology labs. This is opening new markets and use cases, particularly in pharma R&D, synthetic biology, and precision medicine.

Key Competitors

Imaging Technologies

• Revvity
• Zeiss Microscopy
• Nikon Instruments Inc.
• Leica Microsystems
• Evident Scientific
• Bruker Corporation
• JEOL Ltd.
• Hitachi High-Tech Corporation
• PerkinElmer Inc.
• Molecular Devices LLC
• GE Healthcare Life Sciences
• Yokogawa Electric Corporation
• Amnis Corporation (part of Luminex Corporation)
• Cytek(R)
• Chemometec A/S

Cytometric Technologies

• BD Biosciences
• Beckman Coulter (Danaher Corporation)
• Miltenyi Biotec
• Sony Biotechnology Inc.
• Fluidigm Corporation
• Amnis Corporation (part of Luminex Corporation)
• Nexcleom Bioscience LLC
• Chemometec A/S

Cell Culture Technologies

• Corning Incorporated
• Greiner Bio-One International GmbH
• Thermo Fisher Scientific
• Lonza Group
• InSphero AG
• Kuraray Co., Ltd.
• Sartorius AG
• Eppendorf AG
• Appilkon Biotechnology (part of Getinge)
• Merck KGaA
• GE Healthcare Life Sciences
• Cellares
• CellulaRevolution
• TissenBioFarm
• Scinobuh Biotech

Cell Separation Technologies

• Miltenyi Biotec
• BD Biosciences
• Beckman Coulter (Danaher Corporation)
• Fluidigm Corporation
• Dolomite Microfluidics

Growth Drivers

• Advances in research technologies, particularly in CRISPR/Cas9, gene editing, and NGS, are revolutionizing research capabilities, enabling precision gene editing and rapid genetic sequencing, and driving innovation in gene therapy and oncology. These technologies allow researchers to edit genes precisely, expand study areas, and accelerate discoveries in oncology, genetics, and personalized medicine. The continued development and integration of AI and automation are also improving efficiency and reproducibility in lab processes.
• Demand for personalized therapies and regenerative medicine is leading to greater emphasis on cell-based therapies, including stem cell therapies and gene-modified immune cells. Companies are focusing on the development of cell therapy solutions, such as stem cells, which are becoming pivotal in regenerative medicine in treating diseases like Alzheimer's, diabetes, and heart disease.
• The global rise in chronic diseases, including cancer, diabetes, and cardiovascular diseases, is driving demand for more advanced research tools and solutions. This has led to increased funding and innovation in fields like regenerative medicine and gene therapy, with a focus on personalized treatment options to manage these conditions more effectively.
• Strategic partnerships between academic institutions, biotech firms, and pharmaceutical companies are key drivers of growth in the Cell Biology Research Market. These collaborations enable the pooling of expertise, resources, and funding, accelerating the pace of innovation and facilitating the development of new therapies and research tools.
• The evolving regulatory landscape, particularly for gene editing and stem cell therapies, is facilitating market growth. Government and regulatory bodies' support for biotechnology, clinical trials, and product approvals is strengthening. This signals a regulatory environment conducive to research and commercialization and encourages innovation in the field of cell biology research.

Growth Restraints

• The high R&D cost of advanced cell biology research tools and technologies, such as gene editing platforms and high-throughput sequencing systems, remains a significant barrier. Research institutions and biotech companies face high initial investments, which can slow down innovation. It also hinders the affordability of these technologies for smaller organizations or labs with limited budgets.
• There is a global shortage of skilled professionals capable of working with advanced cell biology research technologies, such as CRISPR/Cas9, NGS, and PCR. Specialized training and education programs to meet the increasing demand for qualified personnel are critical. Without an adequately trained workforce, the adoption and effective use of these technologies can be hindered.
• Complexity and technical limitations of tools in terms of precision, reproducibility, and scalability still occur despite rapid technological advancements. Challenges in data interpretation from NGS or the efficiency of gene editing still need to be addressed.
• Concerns regarding data privacy and security have become more prominent as more cell biology research is conducted using patient genetic data and sensitive biological information. Stricter data protection regulations, such as GDPR, pose challenges for companies and research institutions managing large datasets. Any breaches in security could undermine trust in the technologies and slow market growth.

Table of Contents

Research Scope

• Scope of Analysis
• Segmentation

Growth Environment: Transformation in the Cell Biology Research Market

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8
• The Impact of the Top 3 Strategic Imperatives on the Cell Biology Research Industry

Ecosystem in the Cell Biology Research Market

• Competitive Environment
• Key Competitors

Growth Generator in the Cell Biology Research Market

• Growth Metrics
• Growth Drivers
• Growth Restraints
• Forecast Considerations
• Revenue Forecast
• Revenue Forecast by Product
• Revenue Forecast by End User
• Revenue Forecast by Technology
• Revenue Forecast by Region
• Revenue Forecast Analysis
• Revenue Forecast Analysis by Product
• Revenue Forecast Analysis by End User
• Revenue Forecast Analysis by Technology
• Revenue Forecast Analysis by Region
• Pricing Trends and Forecast Analysis
• Revenue Share
• Company Matrix
• Company Portfolio
• Revenue Share Analysis

Companies to Watch: Single-Cell Analysis

• Companies to Watch: Live-Cell Imaging
• Companies to Watch: High-Throughput Screening
• Companies to Watch: Flow Cytometry
• Companies to Watch: Cell Culture
• Companies to Watch: CRISPR and Gene Editing
• Companies to Watch: Others*

Growth Generator: Instruments

• Growth Metrics
• Revenue Forecast
• Revenue Forecast by Region
• Forecast Analysis

Growth Generator: Consumables and Reagents

• Growth Metrics
• Revenue Forecast
• Revenue Forecast by Region
• Forecast Analysis

Growth Generator: Software

• Growth Metrics
• Revenue Forecast
• Revenue Forecast by Region
• Forecast Analysis

Growth Opportunity Universe in the Cell Biology Research Market

• Growth Opportunity 1: Create Software Solutions for Workflow Integration
• Growth Opportunity 2: Combine Single-Cell Analysis with Genomics and Gene Editing Tools
• Growth Opportunity 3: Develop Custom Solutions for Biopharma and Translational Research

Appendix & Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• List of Exhibits
• Legal Disclaimer